A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374 , 1423 ...

ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A) receptor antagonist avosentan in patients with diabetic nephropathy. The study ...

Endothelin (ET) is a recently discovered 21 ... The effects of ET are mediated through interaction with two classes of cell surface receptors. The type A receptor (ET-A) has been associated ...